Across TCGA pan-cancer cohorts, HOXC8 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated HOXC8 data layer compared with 29 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher HOXC8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HOXC8 expression acts as an unfavorable survival marker.
SARC are the cancer types where HOXC8 Mutation most reproducibly stratifies survival.